ClinicalTrials.gg
CompletedNCT06179108Updated Oct 22, 2025Results posted

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

A Phase 2 interventional study of LB-102 in Schizophrenia, sponsored by LB Pharmaceuticals Inc.. Completed at 25 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by LB Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
359
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
157th of 1,319
359 · median 66
Started
2023
with 39 others
Phase 2
217 of 1,465
11 open now
Registered
1,341st of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 157th largest by enrollment of the 1,319 interventional ones that give a count, is one of 40 that started in 2023, is one of 217 in phase 2, and was the 1,341st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.

Read the detailed description

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to examine the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. The primary objective of the study is to assess the efficacy of LB-102 versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores at day 28 in approximately 350 adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate improvement in CGI-S, PANSS subscale and Marder Factor scores, safety and tolerability, and pharmacokinetics in adult inpatients with a DSM-5 diagnosis of schizophrenia. The duration of treatment of the study is 28 days (4 weeks). Patients in this study will be randomized 3:3:3:1 to receive either: placebo, 50 mg QD LB-102, 75 mg QD LB-102, or 100 mg QD LB-102; that is, \~105 patients will get placebo, \~105 will get 50 mg LB-102 QD, \~105 will get 75 mg LB-102 QD, \~35 will get 100 mg LB-102 QD. LB-102 will be dosed orally once a day. Pharmacokinetic data will be measured for the first 60 patients in this study.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient will be eligible for inclusion in the study if they meet all of the following criteria:

  1. Patient who is able to provide written (as required by Institutional Review Board [IRB]) prior to the initiation of any protocol-required procedures.
  2. Must be willing to be hospitalized for the duration of the inpatient period of the study.
  3. Have stable living environment when not in a hospital.
  4. Male and female patients 18 to 55 years of age inclusive at the time of informed consent with a diagnosis of schizophrenia as defined by criteria and confirmed by the MINI 7.0.2 .
  5. (BMI) must be ≥18 and ≤40 kg/m2.
  6. Patient who experiencing an acute exacerbation of psychotic symptoms, AND the patient requires hospitalization OR if already an inpatient at Screening, has been hospitalized for onset \< 2 weeks for the current exacerbation.
  7. Patients who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by meeting ALL of the following criteria at the Screening and Baseline visits:

    • Total PANSS score between 80 and 120, inclusive, and
    • Score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items: Item 1 (P1; delusions), Item 2 (P2; conceptual disorganization), Item 3 (P3; hallucinatory behavior), Item 6 (P6; suspiciousness/persecution), and
    • CGI-S score ≥4 (moderately to severely ill).
  8. Have received previous antipsychotic treatment (dose and duration as per the label) and who showed a previous good response to such antipsychotic treatment (other than clozapine) in the last 12 months, according to the Investigator's opinion.
  9. Have history of relapse and/or exacerbation of symptoms when they were not receiving antipsychotic treatment.
  10. Patients willing to discontinue all prohibited psychotropic medications prior to Screening, if determined to be clinically appropriate by the Investigator, and not for the sole purpose of inclusion in the trial.

Exclusion criteria

Exclusion Criteria:

A patient will be excluded from the study if they meet any of the following criteria:

Sex and Reproductive Status

  1. Sexually active females of and male patients who are not practicing 2 different methods of with their partner during the trial and for 30 days after the last dose of trial medication or who would not remain abstinent during the trial and for 30 days after the last dose.
  2. Females who are breastfeeding or who have a positive pregnancy test result prior to receiving trial medication.
  3. Patients who presented with a first episode of schizophrenia.
  4. Improvement of ≥20% in total PANSS score between the Screening and Baseline assessments.
  5. History of treatment resistance to schizophrenia medications defined as failure to respond to 2 adequate courses of pharmacotherapy (dose and duration as per the label) or required clozapine within the last 12 months.
  6. Current Axis I diagnosis other than schizophrenia.
  7. Risk for suicidal behavior during the study.
  8. Risk of violent or destructive behavior.
  9. Patients with tardive dyskinesia.
  10. Patients with a score of 3 on the Barnes Akathisia Rating Scale (BARS) global clinical assessment of akathisia.
  11. Patients who met DSM-5 criteria for substance abuse or dependence within the past 1 year.
  12. Patients with hypothyroidism or hyperthyroidism or clinically significant abnormal thyroid function.
  13. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
  14. Patients with insulin-dependent diabetes mellitus (i.e., any patient using insulin) are excluded. Patients with non-insulin-dependent diabetes mellitus may be eligible for the trial if their condition is stable as determined by satisfying ALL of the following criteria:

    • Glycosylated () \<7.0%, and
    • Screening glucose must have been ≤125 mg/dL or ≤6.94 mmol/L (fasting) or \<200 mg/dL or \<11.1 mmol/L (nonfasting), and
    • Patient had been maintained on a stable regimen of oral antidiabetic medication(s) for at least 28 days prior to Screening or diabetes had been well controlled by diet for at least 28 days prior to Screening, and
    • Patient had no hospitalizations within the 12 months prior to Screening due to diabetes or complications related to diabetes, and
    • Patient's diabetes should not be newly diagnosed during Screening for the trial.
  15. Patients with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension
  16. Patients with known ischemic heart disease or any history of myocardial infarction, congestive heart failure.
  17. Patients with epilepsy or a history of seizures.
  18. Patients with a positive urine drug screen or a positive blood alcohol test.
  19. Patients with a history of alcohol use or substance use disorder (by DSM-5 criteria) within 12 months of Screening or a positive screen for drugs of abuse at Screening.
  20. The following laboratory test results are exclusionary:

    • ≤75,000/µL or ≤75×109/L
    • Hemoglobin ≤9 g/dL or ≤90 g/L
    • Neutrophils, absolute ≤1000/µL or ≤1×109/L
    • and ALT >2 × (ULN)
    • CPK >3 × ULN, unless discussed with and approved by the Medical Monitor
    • Creatinine ≥2 mg/dL or ≥176.8 µmol/L
    • Estimated of \<45 mL/min, calculated using the Cockcroft-Gault equation, at Screening
    • HbA1c ≥7.0%
    • Abnormal free T4 (during Screening), unless discussed with and approved by the Medical Monitor.
  21. Clinically significant abnormal finding on the triplicate set of (ECGs) or evidence of any of the following cardiac conduction abnormalities at Screening.
  22. Patients who are currently taking oral antipsychotic medications, monoamine oxidase inhibitors (MAOIs), anticonvulsants (e.g., lamotrigine, Depakote), tricyclic antidepressants (e.g., imipramine, desipramine), selective serotonin reuptake inhibitors, and any other antidepressants or any other psychoactive medications (except lorazepam, zolpidem, zaleplon, eszopiclone, or similar benzodiazepines, diphenhydramine, benztropine, and propranolol). The medications should not be discontinued solely to make the patient eligible for enrollment in the study.
  23. Patients who received electroconvulsive therapy, or Transcranial Magnetic Stimulation (TMS).
  24. Patients with a history of neuroleptic malignant syndrome.
  25. Patients with a history of allergic response
  26. Prisoners or patients who were compulsorily detained (involuntarily hospitalized) for treatment of either a psychiatric or physical illness or have been in the last 6 months prior to the Screening Visit
  27. Patients who have participated in another clinical study in which they received an experimental or drug agent within 3 months of Screening.

    -

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
359 participants (actual)

Study arms

  • Experimental
    LB-102, 50 mg QD

    Oral LB-102: 50 mg (n \~ 105)

    Drug: LB-102

  • Experimental
    LB-102, 75 mg QD

    Oral LB-102: 75 mg (n \~ 105)

    Drug: LB-102

  • Experimental
    LB-102, 100 mg

    Oral LB-102: 100 mg (n \~ 35)

    Drug: LB-102

  • Placebo comparator
    Placebo comparator

    Drug: Placebo Matched placebo tablets

    Drug: LB-102

Interventions

  • DrugLB-102

    LB-102 is a dopamine D2/3 and 5HT7 antagonist.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 4 in the PANSS Total Score

    The Positive and Negative Syndrome Scale (PANSS) is a scale used for measuring symptom severity of patients with schizophrenia. The PANSS rating is composed of 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Patients are scored from 1 to 7 on each symptom scale. The total score of the PANSS is a minimum of 30 and a maximum of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms whereas a higher PANSS total value represents a worse outcome

    Time frame: Baseline to Day 28 (4 weeks)

Secondary outcomes

  1. Change From Baseline to Week 4 in the CGI-S Score

    The Clinical Global Impressions-Severity (CGI-S) rates illness severity on a scale from 1 to 7 and has been shown to correlate with PANSS. The CGI-S is rated on a 7-point scale commonly used in clinical settings and research to evaluate the severity of symptoms and treatment responses in patients with mental disorders. The CGI-S specifically focuses on the severity of illness at the time of assessment, where clinicians assess the patient's current condition relative to their past. The scoring is for the CGI-S:1-normal, not at all ill, 2-Borderline mentally ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, and 7-Extremely ill. The higher the score the more ill the patient is.

    Time frame: 28 days

07

Results

Posted Oct 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneLB-102, 50 mg QDLB-102, 75 mg QDLB-102, 100 mg QDPlacebo Comparator
Started10710836108
Completed76802283
Not completed31281425
Withdrew: Withdrawal by subject16191011
Withdrew: Lost to follow-up12419
Withdrew: Adverse event2332
Withdrew: Protocol violation0101
Withdrew: Physician decision1100
Withdrew: Lack of efficacy0001
Withdrew: Death0001

Outcome measures

PrimaryChange From Baseline to Week 4 in the PANSS Total Score

The Positive and Negative Syndrome Scale (PANSS) is a scale used for measuring symptom severity of patients with schizophrenia. The PANSS rating is composed of 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Patients are scored from 1 to 7 on each symptom scale. The total score of the PANSS is a minimum of 30 and a maximum of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms whereas a higher PANSS total value represents a worse outcome

Time frame:
Baseline to Day 28 (4 weeks)
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 4 in the PANSS Total Score
score on a scaleLB-102, 50 mg QDLB-102, 75 mg QDLB-102, 100 mgPlacebo Comparator
Change From Baseline to Week 4 in the PANSS Total Score-14.28 ± 1.097-13.95 ± 1.108-16.08 ± 1.906-9.27 ± 1.078
Statistical analysis
  • LB-102, 50 mg QD vs Placebo Comparator · Mixed Models Analysis · p = 0.0009 (Hochberg's step-down procedure was adopted to control type I error across the 50 and 75 mg arms.)MMRM included treatment group, pooled study site, visit, visit by treatment interaction and baseline total PANSS score.
  • LB-102, 75 mg QD vs Placebo Comparator · Mixed Models Analysis · p = 0.0022 (Hochberg's step-down procedure was adopted to control type I error across the 50 and 75 mg arms.)MMRM included treatment group, pooled study site, visit, visit by treatment interaction and baseline total PANSS score.
  • LB-102, 100 mg vs Placebo Comparator · Mixed Models Analysis · p = .0017MMRM included treatment group, pooled study site, visit, visit by treatment interaction and baseline total PANSS score.
SecondaryChange From Baseline to Week 4 in the CGI-S Score

The Clinical Global Impressions-Severity (CGI-S) rates illness severity on a scale from 1 to 7 and has been shown to correlate with PANSS. The CGI-S is rated on a 7-point scale commonly used in clinical settings and research to evaluate the severity of symptoms and treatment responses in patients with mental disorders. The CGI-S specifically focuses on the severity of illness at the time of assessment, where clinicians assess the patient's current condition relative to their past. The scoring is for the CGI-S:1-normal, not at all ill, 2-Borderline mentally ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, and 7-Extremely ill. The higher the score the more ill the patient is.

Time frame:
28 days
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 4 in the CGI-S Score
score on a scaleLB-102, 50 mg QDLB-102, 75 mg QDLB-102, 100 mgPlacebo Comparator
Change From Baseline to Week 4 in the CGI-S Score-.72 ± 0.076-.67 ± 0.075-.84 ± 0.136-.39 ± 0.074
Statistical analysis
  • LB-102, 50 mg QD vs Placebo Comparator · Mixed Models Analysis · p = 0.0008MMRM included treatment group, pooled study site, visit, visit by treatment interaction and baseline CGI-S score.
  • LB-102, 75 mg QD vs Placebo Comparator · Mixed Models Analysis · p = 0.0048MMRM included treatment group, pooled study site, visit, visit by treatment interaction and baseline CGI-S score.
  • LB-102, 100 mg vs Placebo Comparator · Mixed Models Analysis · p = 0.0026MMRM included treatment group, pooled study site, visit, visit by treatment interaction and baseline CGI-S score.

Adverse events

Collected over From Screening to study day 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LB-102, 50 mg QD0/107 (0%)1/107 (0.9%)74/107 (69.2%)
LB-102, 75 mg QD0/108 (0%)1/108 (0.9%)62/108 (57.4%)
LB-102, 100 mg QD0/36 (0%)1/36 (2.8%)27/36 (75%)
Placebo Comparator1/108 (0.9%)2/108 (1.9%)60/108 (55.6%)
Most frequent serious events
Most frequent serious events
EventLB-102, 50 mg QDLB-102, 75 mg QDLB-102, 100 mg QDPlacebo Comparator
PsychosisPsychiatric disorders0/1070/1081/361/108
Suicidal ideationPsychiatric disorders1/1070/1080/360/108
DeathGeneral disorders0/1070/1080/361/108
DystoniaNervous system disorders0/1071/1080/360/108
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLB-102, 50 mg QDLB-102, 75 mg QDLB-102, 100 mg QDPlacebo Comparator
InsomniaPsychiatric disorders27/10723/10814/3624/108
Weight increasedInvestigations13/1078/1083/364/108
HeadacheNervous system disorders12/1079/1082/3610/108
AnxietyPsychiatric disorders10/1079/1084/369/108
AgitationPsychiatric disorders11/1076/1084/3610/108
HyperprolactinaemiaEndocrine disorders4/1072/1083/360/108
Blood prolactin increasedInvestigations7/1076/1083/360/108
Blood creatine phosphokinase increasedInvestigations4/1071/1082/363/108
Alanine aminotransferase increasedInvestigations3/1071/1082/361/108
SomnolenceNervous system disorders1/1074/1082/360/108

Baseline characteristics

Age, Continuous
Age, Continuous(years)LB-102, 50 mg QDLB-102, 75 mg QDLB-102, 100 mgPlacebo ComparatorTotal
Mean39.0 ± 9.6439.2 ± 9.1739.1 ± 9.1939.1 ± 9.1139.1 ± 9.26
Sex: Female, Male
Sex: Female, Male(Participants)LB-102, 50 mg QDLB-102, 75 mg QDLB-102, 100 mgPlacebo ComparatorTotal
Female201882369
Male87902885290
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LB-102, 50 mg QDLB-102, 75 mg QDLB-102, 100 mgPlacebo ComparatorTotal
American Indian or Alaska Native02002
Asian02013
Native Hawaiian or Other Pacific Islander00000
Black or African American87832580275
White171892468
More than one race21104
Unknown or Not Reported12137
08

Study locations

25 sites
  • Pillar Clinical Research
    Bentonville, Arkansas 72712, United States
  • Woodland Internation Research Group
    Little Rock, Arkansas 72211, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • CelExel Clinical Innovations
    Bellflower, California 90706, United States
  • Synexus
    Cerritos, California 90703, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • CelExel CNS
    Garden Grove, California 92845, United States
  • Synergy Research
    Lemon Grove, California 91945, United States
  • CenExel CIT Riverside
    Riverside, California 92506, United States
  • NRC Research Institute
    Santa Ana, California 92705, United States
  • Behavioral Clinical Research, Inc.
    Hollywood, Florida 33021, United States
  • CenExel RCA
    Hollywood, Florida 33024, United States
  • Segal Institute for Clinical Research
    Miami Lakes, Florida 33016, United States
  • CenExel ACMR
    Atlanta, Georgia 30331, United States
  • CenExel iResearch
    Decatur, Georgia 30030, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Pillar Clinical Research
    Chicago, Illinois 60641, United States
  • CenExel CBH
    Gaithersburg, Maryland 20877, United States
  • CenExel HRI
    Berlin, New Jersey 08009, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10314, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Neuro-Behavioral Clinical Research
    North Canton, Ohio 44720, United States
  • Community Clinical Research
    Austin, Texas 78754, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Pillar Clinical Research
    Richardson, Texas 75080, United States
09

References and documents

Publications

  • Grattan V, Vaino AR, Prensky Z, Hixon MS. Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7. ACS Omega. 2019 Aug 15;4(9):14151-14154. doi: 10.1021/acsomega.9b02144. eCollection 2019 Aug 27. PubMed 31497735 ↗
  • Biernat L, Grattan VT, Hixon MS, Prensky Z, Vaino AR. A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor. Psychopharmacology (Berl). 2022 Sep;239(9):3009-3018. doi: 10.1007/s00213-022-06185-7. Epub 2022 Jul 16. PubMed 35841422 ↗
  • Eramo A, Correll CU, Walling DP, Kakar R, Bassani N, Callahan L, Lee BP, Prensky Z, Vaino AR, Kane JM. Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2026 Jul 1;83(7):682-693. doi: 10.1001/jamapsychiatry.2026.0428. PubMed 42018313 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2024, 12 months.

Results were first posted in Oct 2025, 10 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 12 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 21, 2023
StartActual
Nov 29, 2023
Primary completionActual
Dec 4, 2024
CompletionActual
Dec 4, 2024
Results first posted
Oct 22, 2025
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06179108
Lead sponsor
LB Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Dec 21, 2023
Start date
Nov 29, 2023
Primary completion
Dec 4, 2024
Completion
Dec 4, 2024
Results posted
Oct 22, 2025
Last update
Oct 22, 2025

Study contacts

John Kane, MD
principal investigator · The Zucker Hillside Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LB-102

Start the discussion